查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439939

HPV 检测/巴氏试验 - 全球市场考量、竞争状况、市场预测 (2030)

HPV Testing and Pap Test - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按订单生产 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2023年全球HPV检测/巴氏试验市场规模为33亿美元，到2030年将达47.2亿美元，预计2024-2030年期间复合年增长率为6.17%。由于子宫颈癌盛行率上升和世界各地筛检计画的增加等因素，预计该市场将蓬勃发展。对 HPV 检测和巴氏抹片检测的认识的提高也是预测期内（2024-2030 年）HPV 检测和巴氏抹片检测市场收入成长的因素之一。

HPV 检测/巴氏试验市场动态

HPV 检测和巴氏抹片检测市场的主要驱动因素之一是子宫颈癌盛行率的上升。子宫颈癌是一种始于子宫颈细胞的癌症，子宫颈是子宫与阴道相连的下部。子宫颈癌患者数量的增加导致人们对预先筛检和检测的意识增强，从而导致 HPV 检测和巴氏抹片检测市场的成长。

根据世界卫生组织2022年公布的数据，子宫颈癌是全球女性第四大常见癌症，预计2020年新增病例为60.4万例，死亡人数为34.2万人。2020年全球约90%的新增病例和死亡病例发生在低收入和中等收入国家。

因此，育龄妇女子宫颈癌盛行率不断上升，增加了对 HPV 检测/巴氏抹片检测的需求，预计将在 2024-2030 年预测期内推动市场成长。

此外，政府机构加强提高人们对子宫颈癌的认识，进一步扩大了 HPV 筛检市场，并推动了 HPV 检测/巴氏抹片检查市场的成长。

例如，2020年World Health Assembly通过了一项全球策略，加速消除子宫颈癌这个公共卫生问题。消除子宫颈癌的定义是达到每年每 10 万名妇女中子宫颈癌病例少于 4 例的国家。为了在 21 世纪末达到这一门槛，世卫组织设定了到 2030 年 70% 的女性在 35 岁时接受高性能检测的目标，并在 45 岁时再次接受高水平检测。Masu。因此，在 2024 年至 2030 年的预测期内，将推动 HPV 检测和巴氏抹片检测市场的成长。

此外，HPV 筛检产品开发的进步正在为 HPV 检测和巴氏抹片检测市场的成长带来利润丰厚的成长机会。Qiagen 等公司提供利用先进技术检测 HPV DNA 的测试，例如 Capture 2 测试，可检测子宫颈样本中是否存在 13 种高危险 HPV 类型。

COVID-19 对 HPV 检测和巴氏抹片检测市场产生了负面影响。COVID-19 法规已使许多国家处于封锁状态，导致卫生服务下降，包括各种疾病的诊断。2020 年，随着COVID-19 大流行在全球升级，包括癌症筛检在内的许多不同的选择性医疗程序被推迟，以优先考虑其他紧急需求并降低传播COVID-19 的风险。事实证明确实如此。因此，癌症筛检显着下降，影响了 HPV 检测和巴氏抹片检测市场的收入成长。

此外，推出针对该病毒的HPV疫苗以确保减少子宫颈癌是HPV检测和巴氏试验市场成长的限制因素之一，预计该市场将在2024-2030年预测期内成长。有影响

HPV检测/巴氏抹片检测市场区隔分析

在HPV检测和巴氏试验市场的应用领域中，子宫颈癌在2023年占据最大的市场占有率。这被认为是由于近年来子宫颈癌筛检测试的增加。

本报告研究和分析了全球 HPV 检测和巴氏检测市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第一章 HPV 检测/巴氏抹片检测市场报告简介

第二章 HPV 检测与巴氏抹片检测市场摘要

  • 调查范围
  • 市场概况
  • 竞争评估

第三章 HPV检测/巴氏抹片检测市场主要因素分析

  • HPV检测和巴氏试验市场的驱动因素
  • HPV检测/巴氏抹片检测市场的抑制因素与挑战
  • HPV 检测/巴氏抹片检测市场机会

第四章 HPV 检测与巴氏抹片检测市场的波特五力分析

第五章 COVID-19对HPV检测与巴氏抹片检测市场的影响分析

第六章 HPV检测/巴氏试验市场布局

  • 按测试类型
    • 初级 HPV 检测
    • 玻璃组合检查
    • 巴氏抹片检查
  • 按用途
    • 子宫颈癌
    • 阴道癌
    • 其他
  • 按技术类型
    • 聚合酶链反应
  • 按最终用户
    • 医院、诊所
    • 诊断实验室
  • 区域
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第七章 HPV 检测/巴氏抹片检测市场公司及产品概况

  • Arbor Vita Corporation
  • Danaher Corporation (Cepheid)
  • Seegene Inc.
  • Becton, Dickinson and Company
  • TruScreen
  • Abbott Laboratories
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • OncoHealth Corporation
  • Takara Bio Inc.
  • Promega Corporation
  • Quest Diagnostics
  • Femasys Inc.
  • Mylab Discovery Solutions Pvt Ltd.
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • Nurx

第8章 KOL观点

第9章 专案方法

第10章 关于 DelveInsight

第11章 免责声明与联络我们

Product Code: DIMDCL0620

HPV Testing And PAP Test Market By Test Type (Primary HPV Testing, Co-Testing, And Pap Test), By Application (Cervical Cancer, Vaginal Cancer, And Others), By Technology Type (Polymerase Chain Reaction, And Others), By End-User (Hospitals And Clinics, Diagnostic Laboratories, And Others) by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to rising prevalence of cervical cancer and increased awareness

The global HPV testing and Pap test market was valued at USD 3.30 billion in 2023, growing at a CAGR of 6.17% during the forecast period from 2024 to 2030 to reach USD 4.72 billion by 2030. The HPV testing and Pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2024-2030).

HPV Testing And PAP Test Market Dynamics:

One of the major factors which are driving the HPV testing and pap test market is the rising prevalence of cervical cancer. Cervical cancer is a type of cancer that occurs in the cells of the cervix which is the lower part of the uterus that connects to the vagina. The increase in the rate of cervical cases has created an awareness for prior screening and testing which has led to a growth in the HPV testing and pap test market.

The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries.

Thus, the increasing prevalence of cervical cancer among women of reproductive age is increasing the demand for HPV testing and pap test, which is anticipated to boost the market's growth over the forecast period from 2024-2030.

Moreover, increasing initiatives by government bodies to create awareness for cervical cancer has further increased the market for HPV screening thereby fueling the market growth for HPV testing and pap test.

For instance, the World Health Assembly in 2020 adopted the global strategy to accelerate the elimination of cervical cancer as a public health problem. The definition of elimination of cervical cancer has been set up as a country reaching the threshold of fewer than 4 cases of cervical cancer per 100,000 women per year. To reach this threshold by the end of the 21st century, WHO has set up a target to be reached by 2030 by screening 70% of women with a high-performance test by 35, and again by 45 years of age. Thus, driving the growth of the HPV testing and pap test market in the forecast period of 2024-2030.

Furthermore, advancement in product development for the screening of HPV has led to lucrative growth opportunities in the HPV testing and pap test market growth. Companies like Qiagen are having technologically advanced tests that detect HPV DNA such as the Capture 2 test, which detects the presence of 13 high-risk HPV types in the cervical sample.

COVID-19 has adversely impacted the HPV testing and pap test market. Due to COVID-19 restrictions, many countries were in lockdown leading to a decline in healthcare services, including the diagnosis of various diseases. In 2020, with the rising COVID-19 pandemic globally, various elective medical procedures, including cancer screening, were found to be largely put on hold to prioritize other urgent needs and reduce the risk of the spread of COVID-19. This has shown a substantial decline in cancer screening, thereby affecting the revenue growth of the HPV testing and pap test market.

Furthermore, the launch of the HPV vaccine against the virus to ensure the decline in cervical cancer is one of the restraining factors to the growth of the HPV testing and pap test market that will impact the market growth during the forecast period from 2024-2030.

HPV Testing And PAP Test Market Segment Analysis:

HPV testing and Pap test market by Test Type (Primary HPV Testing, Co-Testing, and Pap Test), by Application (Cervical Cancer, Vaginal Cancer, and Others), by Technology Type (Polymerase Chain Reaction, and Others), by End-User (Hospitals And Clinics, Diagnostic Laboratories, and Others), by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the application segment of the HPV testing and pap test market, cervical cancer accounted for the largest market share in the year 2023. This can be ascribed to the increase in cervical cancer screening tests lately.

Cervical cancer screening is an essential part of a woman's routine healthcare. For women of age 30 years and above, an HPV test is recommended for detection. Almost 95% of cervical cancer causes the causative organisms estimated to be the HP virus. The screening helps identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.

The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries. Therefore, the WHO in 2020 adopted the Global strategy towards eliminating cervical cancer as a public health problem and recommends a comprehensive approach to cervical cancer prevention and control.

Furthermore, in September 2018, the Ministers of Health of the Americas, at the Pan American Health Organization initiated an "Its Time to End Cervical Cancer" campaign to reduce cervical cancer by 2030. To accomplish this, the plan aims to strengthen primary prevention through information and education and HPV vaccination, as well as improve cervical cancer screening and treatment of precancerous lesions, and strengthen access to cancer diagnosis, treatment, rehabilitation, and palliative care.

All these increases in cervical cancer numbers and subsequent awareness programs for the same correspond to the increased market share of the segment, thereby increasing the market growth for the HPV testing and pap test market.

North America is expected to dominate the overall HPV Testing And PAP Test Market:

Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region.

As per CDC 2022 data, each year in the US, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Hispanic women have the highest rates of developing cervical cancer, and Black women have the highest rates of dying from cervical cancer. Therefore, such numbers indicate considerable market growth in this region.

Therefore, with the rising cases of cervical cancer in the region, the government has adopted various awareness programs to decrease the incidence rate of the disease. A few of them are the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening, the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cervical cancer screening. This is one of the major factors expected to drive the North American market for HPV testing and Pap test during the forecast period.

Apart from this, various research and development activities in the North American region for the HPV testing and pap test market are also key factors for the dominance in the market share.

For instance, in 2019, researchers at Massachusetts General Hospital's Center for Systems Biology and Harvard Medical School, Boston presented a novel screening handheld device that uses Artificial Intelligence (AI) for HPV detection. The novel device detects the presence of HPV strains 16 and 18 in a turnaround time of 2 hours.

Therefore, the above-mentioned factors are expected to bolster the growth of the HPV testing and pap test market in the North American region during the forecast period of 2024-2030.

HPV Testing And PAP Test Market Key Players:

Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others.

Recent Developmental Activities In The HPV Testing And PAP Test Market:

In September 2022, Diagnostics player Mylab Discovery Solutions announced the launch of the 'PathoDetect HPV Detection Test', a real-time PCR-based screening solution to detect high-risk types of human papillomaviruses in individuals.

In June 2022, Roche announced the launch of an HPV self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically-validated vaginal sample is analyzed with the Roche Cobas HPV test on a Roche molecular instrument.

Key Takeaways from the HPV Testing And PAP Test Market Report Study

  • Market size analysis for current HPV testing and pap test market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the HPV testing and pap test market.
  • Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
  • Key companies dominating the global HPV testing and pap test market.
  • Various opportunities available for the other competitor in the HPV testing and pap test market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current HPV testing and pap test market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for HPV testing and pap test market growth in the coming future?

Target Audience who can be benefited from this HPV Testing And PAP Test Market Report Study

  • HPV testing and pap test products providers
  • Research organizations and consulting companies
  • HPV testing and pap test -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in HPV testing and pap test
  • Various distribution channels who want to know more about the HPV testing and pap test market and the latest product innovations in the HPV testing and pap test market.

Frequently Asked Questions for HPV Testing and The PAP Test Market:

1. What are HPV testing and pap test?

The HPV test looks for the virus (human papillomavirus) that can cause cell changes on the cervix causing cervical cancer. Whereas, the Pap test (or Pap smear) looks for precancers and cell changes on the cervix that might become cervical cancer if they are not treated appropriately. These tests include microscopic observation of specimens.

2. What is the market for global HPV testing and pap test?

The global HPV testing and pap test market was valued at USD 3.30 billion in 2023, growing at a CAGR of 6.17% during the forecast period from 2024 to 2030 to reach USD 4.72 billion by 2030.

3. What are the drivers for the global HPV testing and pap test market?

The HPV testing and pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2024-2030).

4. Who are the key players operating in the global HPV testing and pap test market?

Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others.

5. Which region has the highest share in the HPV testing and pap test market?

Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region.

Table of Contents

1. HPV testing and pap test market Report Introduction

2. HPV testing and pap test market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. HPV testing and pap test market Key Factors Analysis

  • 3.1. HPV testing and pap test market Drivers
    • 3.1.1. Rising prevalence of cervical cancer
    • 3.1.2. Increase in awareness
    • 3.1.3. Increase in the number of screening programs
  • 3.2. HPV testing and pap test market Restraints and Challenges
    • 3.2.1. Launch of vaccine for cervical cancer prevention
  • 3.3. HPV testing and pap test market Opportunities
    • 3.3.1. Research and development for new diagnostic technologies
    • 3.3.2. The opportunistic market for Low and Middle-Income Countries

4. HPV testing and pap test market Porter's Five Forces Analysis

  • 4.1 .Bargaining Power of Suppliers
  • 4.2 .Bargaining Power of Consumers
  • 4.3 .Threat of New Entrants
  • 4.4 .Threat of Substitutes
  • 4.5 .Competitive Rivalry

5. COVID-19 Impact Analysis on HPV testing and pap test market

6. HPV testing and pap test market Layout

  • 6.1. By Test Type
    • 6.1.1. Primary HPV Testing
    • 6.1.2. Glass Co-Testing
    • 6.1.3. Pap Test
  • 6.2. By Application
    • 6.2.1. Cervical cancer
    • 6.2.2. Vaginal cancer
    • 6.2.3. Others
  • 6.3. By Technology Type
    • 6.3.1. Polymerase chain reaction
    • 6.3.2. Others
  • 6.4. By End User
    • 6.4.1. Hospital and clinics
    • 6.4.2. Diagnostic labs
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States HPV testing and pap test market in USD million (2021-2030)
      • 6.5.1.2. Canada HPV testing and pap test market in USD million (2021-2030)
      • 6.5.1.3. Mexico HPV testing and pap test market in USD million (2021-2030)
    • 6.5.2. Europe
      • 6.5.2.1. France HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.2. Germany HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.3. United Kingdom HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.4. Italy HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.5. Spain HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe HPV testing and pap test market in USD million (2021-2030)
    • 6.5.3. Asia-Pacific
      • 6.5.3.1. China HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.2. Japan HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.3. India HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.4. Australia HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.5. South Korea HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.6. Rest of the Asia Pacific HPV testing and pap test market in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW)
      • 6.5.4.1. Middle East HPV testing and pap test market in USD million (2021-2030)
      • 6.5.4.2. Africa HPV testing and pap test market in USD million (2021-2030)
      • 6.5.4.3. South America HPV testing and pap test market in USD million (2021-2030)

7. HPV testing and pap test market Company and Product Profiles

  • 7.1. Arbor Vita Corporation
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Danaher Corporation (Cepheid)
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Seegene Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Becton, Dickinson and Company
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. TruScreen
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Abbott Laboratories
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Hologic Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Qiagen NV
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. F. Hoffmann-La Roche AG
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. OncoHealth Corporation
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Takara Bio Inc.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Promega Corporation
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Quest Diagnostics
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Femasys Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Mylab Discovery Solutions Pvt Ltd.
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy
  • 7.16. Thermo Fisher Scientific Inc
    • 7.16.1. Company Overview
    • 7.16.2. Company Snapshot
    • 7.16.3. Financial Overview
    • 7.16.4. Product Listing
    • 7.16.5. Entropy
  • 7.17. bioMerieux SA
    • 7.17.1. Company Overview
    • 7.17.2. Company Snapshot
    • 7.17.3. Financial Overview
    • 7.17.4. Product Listing
    • 7.17.5. Entropy
  • 7.18. Nurx
    • 7.18.1. Company Overview
    • 7.18.2. Company Snapshot
    • 7.18.3. Financial Overview
    • 7.18.4. Product Listing
    • 7.18.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on HPV testing and pap test market
  • Table 3: HPV testing and pap test market in Global (2021-2030)
  • Table 4: HPV testing and pap test market in Global by Test Type (2021-2030)
  • Table 5: HPV testing and pap test market in Global by Application (2021-2030)
  • Table 6: HPV testing and pap test market in Global by Technology Type (2021-2030)
  • Table 7: HPV testing and pap test market in Global by End User (2021-2030)
  • Table 8: HPV testing and pap test market in Global by Geography (2021-2030)
  • Table 9: HPV testing and pap test market in North America (2021-2030)
  • Table 10: HPV testing and pap test market in North America by Country (2021-2030)
  • Table 11: HPV testing and pap test market in the US (2021-2030)
  • Table 12: HPV testing and pap test market in Canada (2021-2030)
  • Table 13: HPV testing and pap test market in Mexico (2021-2030)
  • Table 14: HPV testing and pap test market in Europe (2021-2030)
  • Table 15: HPV testing and pap test market in Europe by Country (2021-2030)
  • Table 16: HPV testing and pap test market in France (2021-2030)
  • Table 17: HPV testing and pap test market in Germany (2021-2030)
  • Table 18: HPV testing and pap test market in the United Kingdom (2021-2030)
  • Table 19: HPV testing and pap test market in Italy (2021-2030)
  • Table 20: HPV testing and pap test market in Spain (2021-2030)
  • Table 21: HPV testing and pap test market in Rest of Europe (2021-2030)
  • Table 22: HPV testing and pap test market in APAC (2021-2030)
  • Table 23: HPV testing and pap test market in APAC by Country (2021-2030)
  • Table 24: HPV testing and pap test market in China (2021-2030)
  • Table 25: HPV testing and pap test market in Japan (2021-2030)
  • Table 26: HPV testing and pap test market in India (2021-2030)
  • Table 27: HPV testing and pap test market in Australia (2021-2030)
  • Table 28: HPV testing and pap test market in South Korea (2021-2030)
  • Table 29: HPV testing and pap test market in Rest of APAC (2021-2030)
  • Table 30: HPV testing and pap test market in Rest of World (2021-2030)
  • Table 31: HPV testing and pap test market in RoW by Region (2021-2030)
  • Table 32: HPV testing and pap test market in Middle East (2021-2030)
  • Table 33: HPV testing and pap test market in Africa (2021-2030)
  • Table 34: HPV testing and pap test market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on HPV testing and pap test market
  • Figure 3: HPV testing and pap test market in Global (2021-2030)
  • Figure 4: HPV testing and pap test market in Global by Test Type (2021-2030)
  • Figure 5: HPV testing and pap test market in Global by Application (2021-2030)
  • Figure 6: HPV testing and pap test market in Global by Technology Type (2021-2030)
  • Figure 7: HPV testing and pap test market in Global by End User (2021-2030)
  • Figure 8: HPV testing and pap test market in Global by Geography (2021-2030)
  • Figure 9: HPV testing and pap test market in North America (2021-2030)
  • Figure 10: HPV testing and pap test market in North America by Country (2021-2030)
  • Figure 11: HPV testing and pap test market in the US (2021-2030)
  • Figure 12: HPV testing and pap test market in Canada (2021-2030)
  • Figure 13: HPV testing and pap test market in Mexico (2021-2030)
  • Figure 14: HPV testing and pap test market in Europe (2021-2030)
  • Figure 15: HPV testing and pap test market in Europe by Country (2021-2030)
  • Figure 16: HPV testing and pap test market in France (2021-2030)
  • Figure 17: HPV testing and pap test market in Germany (2021-2030)
  • Figure 18: HPV testing and pap test market in the United Kingdom (2021-2030)
  • Figure 19: HPV testing and pap test market in Italy (2021-2030)
  • Figure 20: HPV testing and pap test market in Spain (2021-2030)
  • Figure 21: HPV testing and pap test market in Rest of Europe (2021-2030)
  • Figure 22: HPV testing and pap test market in APAC (2021-2030)
  • Figure 23: HPV testing and pap test market in APAC by Country (2021-2030)
  • Figure 24: HPV testing and pap test market in China (2021-2030)
  • Figure 25: HPV testing and pap test market in Japan (2021-2030)
  • Figure 26: HPV testing and pap test market in India (2021-2030)
  • Figure 27: HPV testing and pap test market in Australia (2021-2030)
  • Figure 28: HPV testing and pap test market in South Korea (2021-2030)
  • Figure 29: HPV testing and pap test market in Rest of APAC (2021-2030)
  • Figure 30: HPV testing and pap test market in Rest of World (2021-2030)
  • Figure 31: HPV testing and pap test market in RoW by Region (2021-2030)
  • Figure 32: HPV testing and pap test market in Middle East (2021-2030)
  • Figure 33: HPV testing and pap test market in Africa (2021-2030)
  • Figure 34: HPV testing and pap test market in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis